HOOKIPA Pharma (HOOK) announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 and HB-700 development programs, to NeoTrail Therapeutics. The purchase price remains undisclosed. The asset purchase agreement was signed on January 28, 2026, and the transaction is expected to close in the second quarter of 2026, subject to the satisfaction of customary closing conditions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds